Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 85/100

Invivyd Announces its Addition to the Russell 2000 and Russell 3000 Indexes

Key Takeaway: Invivyd, Inc. has been added to the Russell 2000 and Russell 3000 Indexes as part of their annual reconstitution process, effective July 1, 2024. This inclusion provides the company with enhanced visibility among institutional investors and positions it well for future opportunities in the market. The Russell indexes are important benchmarks used by investment managers, which could lead to increased interest in Invivyd's stock. This move aligns with Invivyd's mission to combat viral infectious diseases through innovative monoclonal antibody treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Inclusion in the prestigious Russell 2000 and Russell 3000 Indexes enhances credibility.
  • Membership supports greater visibility among investors and potential for increased investment.
  • Aligns with Invivyd's growth strategy and market presence as a biopharmaceutical company.

Full Press Release Details

WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today.
Membership in the Russell 3000® Index means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as in the appropriate growth and value style indexes. The Russell 3000® Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings, and style attributes. Membership in these indexes is updated annually and remains in place for one year.
The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell 2000® and Russell 3000® Indexes and the Russell U.S. Indexes Reconstitution, visit the "Russell Reconstitution" section on the FTSE Russell website.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Frequently Asked Questions

What is Invivyd, Inc. known for?

Invivyd, Inc. specializes in protection against serious viral infectious diseases.

Which indexes will Invivyd be included in?

Invivyd will be included in the Russell 2000® and Russell 3000® Indexes.

What is the Russell 3000® Index?

The Russell 3000® Index includes the 3,000 largest U.S. traded stocks.

What platform does Invivyd use for antibody development?

Invivyd utilizes the INVYMAB™ platform for monoclonal antibody development.

What authorization did Invivyd receive in March 2024?

In March 2024, Invivyd received emergency use authorization from the FDA.

Last updated: Jul 1, 2024